|
CABG or PCI in Patients With Ischemic Cardiomyopathy
RECRUITINGN/ASponsored by Vastra Gotaland Region
Actively Recruiting
PhaseN/A
SponsorVastra Gotaland Region
Started2022-09-14
Est. completion2028-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05329285
Summary
The STICH-SWEDEHEART trial will compare PCI vs CABG for revascularization of patients with HF and LV systolic dysfunction (LV ejection fraction (LVEF) \<40%) and multi-vessel coronary artery disease.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: 1. Age ≥18 years. 2. Symptomatic HF defined as NYHA HF class II-IV within 1 month of enrolment 3. LVEF ≤ 40% quantified by either echocardiography or gated SPECT ventriculography, or magnetic resonance (MR) or any other recognized assessment of LVEF 4. Meaningful amount of myocardium at risk because of CAD (BCIS myocardial jeopardy score ≥ 6 on a recent (\> 6 months) coronary angiogram); 5. Heart team believes that a meaningful revascularization can be achieved by both PCI or CABG, with complete revascularization defined as residual ischemia in \<10% of the left ventricle 6. Heart team agrees that guideline directed medical therapy (GDMT) has been initiated for ≥1 month in prevalent and newly diagnosed cases. In patients hospitalized with newly diagnosed iLVSD (with or without acute coronary syndrome (ACS)) requiring revascularization before discharge, GDMT needs to be initiated, when possible, in-hospital before randomization, with the expectation that it will be titrated to maximally tolerated doses after revascularization 7. Written informed consent obtained Exclusion Criteria: 1. Previous randomization in the study 2. Decompensated heart failure requiring inotropic /adrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump/ventricular assist device therapy less than 48 hours prior to randomization 3. Recent (\<1 month) type 1 myocardial infarction 4. Recent PCI (\<3 months) 5. Valvular heart disease or any other cardiac conditions (e.g. LV aneurysm) requiring surgical repair/replacement 6. Prohibitive bleeding risk or clinical scenario mandating avoidance of long-term dual antiplatelet therapy 7. Expected survival less than 3 years due to non-cardiac illness 8. Circumstances likely to lead to poor treatment compliance 9. Individuals for whom record in public health databases is not accessible (non-eligibility to public health system, parallel healthcare systems 10. Pregnancy or woman of childbearing potential who is not sterilized or using a medically accepted form of contraception
Conditions2
Coronary Artery DiseaseHeart Disease
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorVastra Gotaland Region
Started2022-09-14
Est. completion2028-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05329285